SCA
IRWD icon

Snowden Capital Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Snowden Capital Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$2K – 1539
2021
Q4 		$2K Buy
+200
New +$2.45K ﹤0.01% 1864

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Snowden Capital Advisors's IRWD Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2022, closing a stake of 200 shares — an estimated $2K sold.

Snowden Capital Advisors first reported a position in IRWD in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 221 funds tracked by Wall St. Rank hold IRWD as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 200 Ironwood Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • Snowden Capital Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Ironwood Pharmaceuticals position peaked at $2K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.